Related Experiment Video
Updated: Jul 3, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Merlin is a potent inhibitor of glioma growth
Ying-Ka Ingar Lau1, Lucas B Murray, Sean S Houshmandi
1Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA.
Abstract:
Neurofibromatosis 2 (NF2) is an inherited cancer syndrome in which affected individuals develop nervous system tumors, including schwannomas, meningiomas, and ependymomas. The NF2 protein merlin (or schwannomin) is a member of the Band 4.1 superfamily of proteins, which serve as linkers between transmembrane proteins and the actin cytoskeleton. In addition to mutational inactivation of the NF2 gene in NF2-associated tumors, mutations and loss of merlin expression have also been reported in other types of cancers. In the present study, we show that merlin expression is dramatically reduced in human malignant gliomas and that reexpression of functional merlin dramatically inhibits both subcutaneous and intracranial growth of human glioma cells in mice. We further show that merlin reexpression inhibits glioma cell proliferation and promotes apoptosis in vivo. Using microarray analysis, we identify altered expression of specific molecules that play key roles in cell proliferation, survival, and motility. These merlin-induced changes of gene expression were confirmed by real-time quantitative PCR, Western blotting, and functional assays. These results indicate that reexpression of merlin correlates with activation of mammalian sterile 20-like 1/2-large tumor suppressor 2 signaling pathway and inhibition of canonical and noncanonical Wnt signals. Collectively, our results show that merlin is a potent inhibitor of high-grade human glioma.
Insights
Neurofibromatosis 2 (NF2) protein merlin is significantly reduced in malignant gliomas. Reexpressing merlin inhibits glioma growth, proliferation, and promotes apoptosis, identifying it as a potent inhibitor of high-grade human glioma.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Neurofibromatosis 2 (NF2) is an inherited cancer syndrome characterized by nervous system tumors.
- The NF2 protein, merlin, links cell surface proteins to the cytoskeleton and is implicated in various cancers.
- Reduced merlin expression is observed in human malignant gliomas.
Purpose of the Study:
- To investigate the role of merlin in high-grade human gliomas.
- To determine if merlin reexpression can inhibit glioma growth and survival.
- To identify molecular pathways affected by merlin in glioma cells.
Main Methods:
- Utilized microarray analysis to identify gene expression changes.
- Confirmed gene expression alterations using real-time quantitative PCR and Western blotting.
- Assessed merlin's effect on glioma cell proliferation, apoptosis, and tumor growth in vivo.
Main Results:
- Merlin expression is dramatically reduced in human malignant gliomas.
- Reexpression of functional merlin significantly inhibited subcutaneous and intracranial glioma growth in mice.
- Merlin reexpression suppressed glioma cell proliferation and induced apoptosis in vivo.
- Identified merlin-induced alterations in genes regulating cell proliferation, survival, and motility.
- Observed correlation between merlin reexpression, activation of MST1/2-LATS2 pathway, and inhibition of Wnt signaling.
Conclusions:
- Merlin acts as a potent inhibitor of high-grade human gliomas.
- Merlin reexpression reverses key oncogenic pathways in glioma cells.
- Restoring merlin function presents a potential therapeutic strategy for malignant gliomas.
